Drug intelligence / Profile preview

ZN-F-6418

Development stage: Unknown
Lead developer: Suzhou Zanrong Pharma
Modality: Small Molecules
Administration: Oral

Overview

ZN-F-6418 is an orally bioavailable small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family, specifically targeting FGFR2 and FGFR3. Developed by Suzhou Zanrong Pharma, the compound is designed to treat advanced solid tumors that harbor FGFR alterations, such as gene fusions, mutations, or amplifications. By selectively inhibiting FGFR signaling, ZN-F-6418 disrupts downstream oncogenic pathways, including the RAS-MAPK and PI3K-AKT cascades, which are critical for tumor cell proliferation and survival. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and preliminary therapeutic activity in patients with refractory solid malignancies.

Targets

FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)

Beyond the preview

Go deeper on ZN-F-6418.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZN-F-6418.

Explore the full profile